Axon damage is a common phenomenon in many neurological diseases, including those of neuroimmunological origin.[1](#ana24630-bib-0001){ref-type="ref"} Indeed, in multiple sclerosis (MS), the degree of axon damage is an important determinant of chronic disability.[2](#ana24630-bib-0002){ref-type="ref"}, [3](#ana24630-bib-0003){ref-type="ref"} However, because the pathological cascades that drive axon damage in MS are not known, only limited understanding of the mechanisms underlying this important aspect of pathology has been possible. In contrast, in neuromyelitis optica (NMO), an autoimmune disease that mainly affects the optic nerve and spinal cord,[4](#ana24630-bib-0004){ref-type="ref"} the autoimmune target has been identified in the majority of patients. Most NMO patients have a specific serum antibody response to aquaporin‐4 (AQP4),[5](#ana24630-bib-0005){ref-type="ref"}, [6](#ana24630-bib-0006){ref-type="ref"}, [7](#ana24630-bib-0007){ref-type="ref"}, [8](#ana24630-bib-0008){ref-type="ref"} a water channel, which in the central nervous system (CNS) is expressed on astrocytes, especially on perivascular and superficial glia limitans processes. Antibodies to AQP4 (AQP4‐Ig \[immunoglobulin\]) are also present in the cerebrospinal fluid (CSF) of NMO patients, although at a lower titer.[8](#ana24630-bib-0008){ref-type="ref"}, [9](#ana24630-bib-0009){ref-type="ref"}, [10](#ana24630-bib-0010){ref-type="ref"} Occurrence of AQP4‐Ig in serum and CSF, loss of astrocytes, deposition of complement, and infiltration of macrophages in NMO lesions together imply a specific immune response against AQP4‐expressing astrocytes.[11](#ana24630-bib-0011){ref-type="ref"}, [12](#ana24630-bib-0012){ref-type="ref"}, [13](#ana24630-bib-0013){ref-type="ref"} Indeed, intraperitoneal injection of NMO serum immunoglobulins containing AQP4‐Ig or of AQP4‐specific recombinant antibodies combined with opening of the blood--brain barrier (BBB) by T‐cell‐mediated inflammation or intracerebral needle injury can produce astrocyte loss and demyelination in rats.[9](#ana24630-bib-0009){ref-type="ref"}, [13](#ana24630-bib-0013){ref-type="ref"}, [14](#ana24630-bib-0014){ref-type="ref"}, [15](#ana24630-bib-0015){ref-type="ref"} Similarly, injection of AQP4‐Ig and human complement into mouse brain induces NMO‐like lesions.[16](#ana24630-bib-0016){ref-type="ref"} The majority of AQP4‐Ig belongs to the IgG~1~ subclass, which can activate the complement cascade upon target binding,[8](#ana24630-bib-0008){ref-type="ref"} and hence the presence of complement and antibody effector function is essential in transfer models that show astrocyte loss. In line with these observations, plasma exchange, which reduces circulating IgG and complement levels, is effective in treating NMO relapses.[17](#ana24630-bib-0017){ref-type="ref"} In addition to astrocyte loss and immunopathology, demyelination and axon damage have been identified histologically in NMO.[18](#ana24630-bib-0018){ref-type="ref"}, [19](#ana24630-bib-0019){ref-type="ref"} Although demyelination has been investigated in some detail in previously reported animal models, the impact of AQP4‐Ig‐mediated astrocyte loss on axons has received less attention.[9](#ana24630-bib-0009){ref-type="ref"}, [13](#ana24630-bib-0013){ref-type="ref"}, [14](#ana24630-bib-0014){ref-type="ref"}, [15](#ana24630-bib-0015){ref-type="ref"}, [16](#ana24630-bib-0016){ref-type="ref"} This is despite the fact that axon damage appears to be an early feature of human pathology[19](#ana24630-bib-0019){ref-type="ref"} and likely underlies some of the residual deficits after NMO relapses. Thus, improved models to study the mechanisms by which AQP4‐Ig‐induced damage spreads from astrocytes to axons are needed.

Here, we use an in vivo two‐photon imaging approach to the mouse spinal cord that we previously established[20](#ana24630-bib-0020){ref-type="ref"}, [21](#ana24630-bib-0021){ref-type="ref"}, [22](#ana24630-bib-0022){ref-type="ref"} to gain insight into AQP4‐Ig‐mediated lesion formation. We found that AQP4‐Ig‐containing samples obtained from NMO patients (as well as a recombinant AQP4‐IgG from a clonotypic plasma blast present in the CSF of an NMO patient) caused acute, dose‐dependent and (human) complement‐mediated loss of astrocytes when applied at the pial surface of the spinal cord at IgG concentrations found intrathecally in NMO.[23](#ana24630-bib-0023){ref-type="ref"} Using combinatorial transgenic labeling of different CNS cell types, we revealed secondary axon damage, which, in onset and extent, correlated with astrocyte loss and AQP4‐IgG titer. This imaging approach will provide a novel way to study, in real time and with single‐cell resolution, how secondary damage emerges after AQP4‐Ig‐mediated astrocyte loss in nascent NMO‐like spinal lesions.

Materials and Methods {#ana24630-sec-0006}
=====================

Animals {#ana24630-sec-0007}
-------

We used 2‐ to 4‐month‐old transgenic male and female mice to visualize astrocytes (*Aldh1l1*:GFP; obtained from MMRRC: strain Tg(Aldh1l1‐EGFP)OFC789Gsat/Mmucd[24](#ana24630-bib-0024){ref-type="ref"}) and axonal morphology (*Thy1*:OFP[25](#ana24630-bib-0025){ref-type="ref"} courtesy of Jeff Lichtman, Harvard University, Cambridge, MA) for in vivo experiments and 3‐ to 5‐week‐old *Aldh1h1*:GFP mice for ex vivo experiments. In some experiments 2‐ to 4‐month‐old C57BL/6 mice were used as transgene‐free controls. *Plp*:CreER × *ROSA*:STOP‐TdTomato mice (Ai14; The Jackson Laboratory, Bar Harbor, ME)[26](#ana24630-bib-0026){ref-type="ref"}, [27](#ana24630-bib-0027){ref-type="ref"}, in which oligodendrocytes are labeled, were used to control for cell‐type specificity (tamoxifen injection proved unnecessary because of constitutive activity of the CreER in adult animals). Tissue samples from AQP4 knockout mice were obtained from Alan Verkman (University of California San Francisco, San Francisco, CA).[28](#ana24630-bib-0028){ref-type="ref"} Animal experiments were conducted in accord with local regulations and were approved by the responsible regulatory agencies.

Patients, Serum/Plasma Samples, and Complement Sources {#ana24630-sec-0008}
------------------------------------------------------

NMO patients were recruited from the Department of Neurology, University of Pecs, (Pecs, Hungary) and from the Department of Neurology, Klinikum rechts der Isar, Technical University of Munich (Munich, Germany). All patients were examined by neurologists specialized in neuroimmunology and fulfilled the diagnostic criteria for NMO based on Wingerchuk\'s criteria.[4](#ana24630-bib-0004){ref-type="ref"} Serum or plasma samples of 4 AQP4‐Ig‐positive individuals were included in this study, 3 of which (referred to as NMO1‐3 below) were used in in vivo experiments. As controls, samples of 3 healthy subjects (ctrl1‐3, below), without signs of an autoimmune disease or infection at the time of blood sampling, were included in cooperation with the blood bank of the Bavarian Red Cross. Blood samples were collected by venipuncture, centrifuged at 3,000rpm for 10 minutes, split into aliquots, frozen for storage at --80 °C, and thawed only on the day of the experiment. All blood samples were tested for being human immunodeficiency virus, hepatitis B virus, and hepatitis C virus negative. All subjects gave written informed consent to the use of their blood samples for research. Moreover, for complement depletion and reconstitution assays, we obtained human C1q‐depleted sera and purified C1q component from Merck Millipore (Billerica, MA).

Acute Brain Slice Preparation {#ana24630-sec-0009}
-----------------------------

Ex vivo acute brain slice experiments were performed as previously described.[29](#ana24630-bib-0029){ref-type="ref"} In brief, brains from *Aldh1l1*:GFP mice were removed, cut centrally into coronal slices (300 µm) in Ringer\'s/artificial cerebrospinal fluid (aCSF; pH 7.4 at 4 °C) containing (in mM): 125 NaCl, 26 NaHCO~3~, 2.5 KCl, 1.25 NaH~2~PO~4~, 2 CaCl~2~, 1 MgCl~2~, and 20 glucose, followed by recovery at 35 °C for 1 hour. Slices were transferred to a recording chamber and continuously superfused with 50ml of recirculating, heated (30 °C), and oxygenated (95% O~2~/5% CO~2~) aCSF (1.5--2.0ml/min). After complement inactivation at 56 °C for 30 minutes, we applied diluted NMO or control sera/plasma (IgG levels adjusted to the values indicated in the figures), together with 4% non‐heat‐inactivated serum from healthy donors (HDs) as a source of complement (referred to as HD serum below), which remained in the aCSF from 0 to 180 minutes of the experiment. Image stacks (∼30 images, 2‐µm z‐spacing) were acquired using a two‐photon microscope (Olympus FV1000 MPE tuned to 910 nm, equipped with a ×25/1.05 numerical aperture \[N.A.\] water dipping cone objective; Olympus, Tokyo, Japan) at 3‐minute intervals for 3 hours.

Surgical Procedures and In Vivo Imaging {#ana24630-sec-0010}
---------------------------------------

Laminectomy surgeries were performed as previously described[21](#ana24630-bib-0021){ref-type="ref"}: Mice were anesthetized by an intraperitoneal injection of ketamine‐xylazine (87mg/kg/13mg/kg, respectively) or meditomidin 0.5mg/kg, midazolam 5mg/kg, and fentanyl 0.05mg/kg. Anesthesia was reapplied as needed (every 60--120 minutes). After a double dorsal laminectomy over the fourth lumbar, L4, and L5 segments, mice were suspended using compact spinal cord clamps.[30](#ana24630-bib-0030){ref-type="ref"} A well around the opening was built using 2‐4% agarose to hold aCSF (as above, glucose omitted or alternatively, in mM: 148.2 NaCl, 3.0 KCl, 0.8 Na~2~HPO~4~, 0.2 NaH~2~PO~4~, 1.4 CaCl~2~, and 0.8 MgCl~2~). An imaging window free from dura was established in the imaging area using a bent hypodermic needle. In some experiments, astrocyte death was verified by addition of ethidium homodimer‐1 (1:500, 0.56mg/ml stock; Invitrogen, Carlsbad, CA).

In vivo imaging of the lumbar spinal cord was performed as previously described.[21](#ana24630-bib-0021){ref-type="ref"}, [31](#ana24630-bib-0031){ref-type="ref"} Briefly, stacks were acquired using two‐photon microscopes (Olympus FV1000 MPE or FVMPE‐RS tuned to 910 nm for green fluorescent protein \[GFP\] alone and 980nm for GFP/OFP \[orange fluorescent protein\], equipped with a ×25/1.05 N.A. water‐dipping cone objective). All light was first filtered through a 690 nm short‐pass dichroic mirror. Fluorescence was collected using a G/R filter set (BA 495‐540, BA 570‐625) mounted in front of gallium arsenide phosphide photomultiplier tubes. Time‐lapse stacks were acquired at 3‐minute intervals for 3 hours (astrocyte loss) or at 15‐minute intervals for 6 hours (axon damage) with the following parameters: 35 images (zoom 1.8--2.0; pixel size: 0.28--0.38 µm) with 1‐µm z‐step. Diluted heat‐inactivated serum/plasma was applied every 30 minutes, supplemented with 20% of non‐heat‐inactivated HD serum as a complement source. Compared to experiments with acute brain slices, a higher concentration was needed, most likely because of restricted penetration and possibly the presence of complement blockers in vivo. Serum/plasma was present in the spinal opening for the initial 90 minutes of the experiment, after which it was replaced with aCSF (at 90 minutes and renewed every 60 minutes until the end of the experiment). Transient delivery of the NMO sample and complement source was designed to induce an acute, well‐defined injury and reduce consumption of sparse patient‐samples. In a set of control experiments using NMO1 samples and HD serum for up to 8 hours continuously, we found no qualitative difference between prolonged and transient applications, although, as expected, astrocyte depletion and the degree of axon swellings was more pronounced after longer exposure to patient IgG and complement. To confirm AQP4 specificity, we also performed experiments using a human IgG~1~ recombinant antibody rAb 7‐5‐53 reconstructed from a clonotypic plasma blast obtained from the CSF of an NMO patient (r‐AQP4‐IgG)[9](#ana24630-bib-0009){ref-type="ref"}. r‐AQP4‐IgG was applied at 1.5 μg/ml of IgG supplemented with 20% of non‐heat‐inactivated HD serum. The rAb ICOS‐5‐2, a divalent human IgG~1~ antibody of unknown specificity, developed from a chronic meningitis patient, served as an isotype control (r‐ctrl‐IgG).

We have previously demonstrated that phototoxicity does not appear to have a measurable impact on the health of spinal axons under such imaging conditions.[21](#ana24630-bib-0021){ref-type="ref"}, [22](#ana24630-bib-0022){ref-type="ref"}, [31](#ana24630-bib-0031){ref-type="ref"}, [32](#ana24630-bib-0032){ref-type="ref"} Moreover, histological analysis confirmed NMO serum‐/plasma‐mediated astrocyte loss in the absence of oligodendrocyte loss in superficial spinal cord layers when no imaging was done (see below and *cf*. Fig [1](#ana24630-fig-0001){ref-type="fig"}G,H). Additionally, axonal pathology could be confirmed in experiments in which only an initial and a final image (at 6 hours) were taken (*cf*. Fig [4](#ana24630-fig-0004){ref-type="fig"}B). To rule out a spurious influence of the transgenic labeling of axons, we performed experiments without imaging using wild‐type (C57BL/6) and transgenic animals and antitubulin staining (see below). The analysis was performed by a scorer blind to the treatment conditions and genotypes and showed a comparable percentage of axonal swellings in spinal cords treated with NMO serum/plasma irrespective of genotype (data not shown).

![NMO patient‐derived samples contain AQP4‐Ig that stains and ablates mouse astrocytes in vitro and in vivo. (A) White matter spinal cord cryosections of *Aldh1l1*:GFP mice (*Aldh*:GFP, left; GFP not shown) and AQP4‐knockout‐mice (AQP4^--/--^, right), stained for astrocytes (GFAP, green), nuclei (DAPI, white), and with an AQP4‐Ig‐containing NMO sample (NMO1, red). (B) Confocal image of a fixed brain slice from an Aldh1l1‐GFP mouse. Box indicates the relative size of a typical time‐lapse area as magnified in (C). (C) Two‐photon image of astrocytes in an acute brain slice. Boxed area time‐lapsed in (D), left column. (D) Time‐lapse images taken from acute brain slices every 3 minutes for 3 hours, showing astrocytes (red arrowheads) that lose fluorescence and die in the presence of a heat‐inactivated AQP4‐Ig‐containing NMO sample (NMO1) and HD serum as a source of complement. A control serum (ctrl1) had no detectable effect under the same conditions. (E) Astrocyte survival over 180 minutes in acute brain slices in the presence of control sera from healthy subjects (ctrl1‐3) and an AQP4‐Ig‐containing NMO serum (NMO1, 300 μg/ml of IgG; n = 3 recordings for each sample; *p* \< 0.0001, log‐rank test). (F) Dose‐response curve of astrocyte survival after 180 minutes for an AQP4‐IgG containing NMO (NMO1) and three control samples (n = 3 recordings for each sample; *p* = 0.0045, Mann--Whitney *U* test, NMO1 vs pooled ctrl1‐3 for 300‐μg/ml IgG concentration). HD serum (4%) as a source of complement was present in all recordings in (E) and (F). (G and H) Histopathological quantification of astrocyte (GFAP; G) and oligodendrocyte (Nogo‐A; H) densities in the superficial spinal cord of wild‐type and *Aldh1l1*:GFP mice after 180‐minute in vivo application of heat‐inactivated AQP4‐Ig‐containing NMO (NMO1) or a control sample (ctrl1) supplemented with HD serum into a laminectomy opening (n = 3 mice for each genotype/treatment combination; GFAP: wild‐type ctrl1 vs NMO1 *p* \< 0.001; Aldh:GFP ctrl1 vs NMO1 *p* \< 0.01; Nogo‐A: no significant differences, D\'Agostino and Pearson\'s normality test, followed by analysis of variance and Holm‐Sidak\'s multiple comparisons test). Scale bars, 10 µm in (A), 500 µm in (B), 20 µm in (C), and 10 µm in (D). Data are presented as mean ± standard error of the mean. AQP4 = aquaporin‐4; DAPI = 4′,6‐diamidino‐2‐phenylindole; GFAP = glial fibrillary acidic protein; GFP = green fluorescent protein; HD = healthy donor; Ig = immunoglobulin; NMO = neuromyelitis optica.](ANA-79-794-g001){#ana24630-fig-0001}

Immunohistochemistry and Histological Analysis {#ana24630-sec-0011}
----------------------------------------------

After transcardiac perfusion with 4% paraformaldehyde (PFA) in 0.01M of phosphate‐buffered saline (1×PBS; in mM: 1.5 KH~2~PO~4~, 2.7 KCl, 8.1 Na~2~HPO~4~, and 137 NaCl), the spinal cord and brain from *Adh1l1*:GFP mice were postfixed for 24 hours in 4% PFA, then dissected and put in sucrose (30%) solution for a further 12 to 24 hours. Subsequently, 20‐µm‐thick cryosections were cut in a cryostat. For staining, NMO1 plasma or serum (and control sera from healthy donors) was used at 1:1,000 in 0.2% Triton X‐100, 10% normal goat serum, and 1% bovine serum albumin in 1×PBS (followed by incubation with appropriate secondary antibodies; antihuman IgG 1:200, ABC‐complex, streptavidin Alexa Fluor 555 1:1,000). Glial fibrillary acidic protein (GFAP) antibody (rat; Invitrogen) was used at a concentration of 1:200 (followed by goat Alexa Fluor 647--conjugated antirat IgG 1:1,000). Sections were mounted in 4′,6‐diamidino‐2‐phenylindole (DAPI)‐containing mounting medium, and image stacks were recorded on a confocal microscope (Olympus FV1000) equipped with × 20/0.8 N.A. and ×60/1.42 N.A. oil‐immersion objectives. For tubulin stainings, we used an Alexa Fluor 647--conjugated antibody to tubulin III beta (mouse; BioLegend) at 1:200 and stained spinal cord whole mounts[22](#ana24630-bib-0022){ref-type="ref"} of wild‐type control (C57BL/6) or *Thy1*:OFP mice that were either treated with NMO or control samples plus HD serum for 6 hours without imaging. Confocal images were taken as described above for GFAP stainings. To control for effects of imaging and transgene expression on astrocyte loss, we performed dorsal laminectomy surgery on wild‐type control (C57BL/6) and *Aldh1l1*:GFP mice as described for imaging above. We applied heat‐inactivated NMO, as well as control samples with HD serum as a complement source as detailed above, but no imaging was performed. Instead, after 3 hours, animals were perfused, their spinal cords embedded in paraffin, and subjected to histopathological analysis according to standardized protocols as described previously.[33](#ana24630-bib-0033){ref-type="ref"} Briefly, immunostaining was performed using the following primary antibodies: rabbit/anti‐GFAP (astrocytes; 1:2,000; code no.: Z0334; Dako, Carpinteria, CA) and mouse/anti‐NogoA (mAb11C7, 1:20,000; kindly provided by M.E. Schwab, Zurich, Switzerland). Bound primary antibodies were visualized using a ready‐to‐use, peroxidase‐based secondary detection system (EnVision; Dako) with 3,3′‐diaminobenzidine as chromogen (hemalaun counterstaining of nuclei). Immunostained sections were scanned using a Panoramic Digital Slide Scanner 250 FLASH II (3DHISTECH Ltd., Budapest, Hungary) at 200 × magnification. Astrocyte and oligodendrocyte densities in the superficial dorsal spinal cord (\<50 μm from pial surface) were counted manually using Panoramic Viewer software (3DHISTECH Ltd.) by a scorer blind to the treatment conditions and genotypes.

AQP4‐Specific Immunoglobulin Depletion From Patient Samples {#ana24630-sec-0012}
-----------------------------------------------------------

HEK293 cells (∼2\*10^9^) expressing C‐terminally His‐tagged AQP4 were lysed in 5ml of nondenaturing base lysis buffer (in mM: NaCl 300, Tris‐HCl \[pH 7.4\] 10, phosphate buffer \[pH 7.4\] 50, imidazol \[pH 7.4\] 10, 200 µl of ethylenedimainetetraacetic acid \[EDTA\]‐free protease inhibitor cocktail, and 5 µl of benzoase) with 1% decyl β‐D‐maltopyranoside for 40 minutes at room temperature. Lysate was centrifuged at 50,000*g* and cleared supernatant incubated with 500 µl of pre‐equilibrated HisPur Cobalt Resin (Life Technologies, Carlsbad, CA) for 1 hours. The resin was spun down and washed thoroughly with washing buffer I (as above, but containing only 0.01% decyl β‐D‐maltopyranoside) multiple times until absorption at 280nm became undetectable. Resin was resuspended in 40ml of 0.03% H~2~O~2~ and agitated at room temperature for 2 hours for oxidation of Co(II) to Co(III), spun down, and washed with wash buffer II (PBS and 100mM of EDTA) to strip away any unoxidized divalent ions.[34](#ana24630-bib-0034){ref-type="ref"} This AQP4 resin was used to deplete antigen‐specific Ig from samples. Control columns were prepared in the same way, however, using sham‐transfected HEK293 cells. For access to sufficient volumes, AQP4‐specific Ig depletion experiments were performed with NMO1 plasma.

AQP4‐Antibody Titration Assay {#ana24630-sec-0013}
-----------------------------

Sera and recombinant Abs were measured at different dilutions using a cell‐based flow cytometry assay. The human glioblastoma cell line, LN18, was stably transduced using a lentiviral vector to overexpress human AQP4‐M23 as previously reported (LN18^AQP4^).[8](#ana24630-bib-0008){ref-type="ref"}, [9](#ana24630-bib-0009){ref-type="ref"} Results were expressed as median fluorescence intensities (MFI) corrected for background binding to a cell line that was transduced with an empty vector (LN18^CTR^). Samples were considered to be positive if the ΔMFI value was above 50 (where ΔMFI is the MFI difference between LN18^AQP4^ and LN18^CTR^, and a measure of the concentration of AQP4‐specific IgG).

Image Processing and Data Analysis {#ana24630-sec-0014}
----------------------------------

Images were processed using the open‐source image analysis software, Fiji[35](#ana24630-bib-0035){ref-type="ref"} and Adobe Creative Suite. Gamma was adjusted linearly in all figure panels; gamma was adjusted nonlinearly in video files to enhance visibility of morphological detail. Percentage of cell loss was defined as percentage of cells that lost \>50% of their fluorescence, which was accompanied by clear changes in morphology (rounding, process blebbing). Axon morphology in a neuroinflammatory setting was staged as described previously.[21](#ana24630-bib-0021){ref-type="ref"}, [22](#ana24630-bib-0022){ref-type="ref"} Only axons that were observable across all time points during the experiment over at least 50 µm were analyzed. Each axonal swelling was verified by observations of morphology within unprocessed three‐dimensional (3D) image stacks. We relinquished scoring the morphological changes of astrocytes and axons blindly, given that the difference between control and NMO experiments was obvious. Data sets were processed with Excel (Microsoft Corporation, Redmond, WA). For survival curves (Figs [1](#ana24630-fig-0001){ref-type="fig"}E, [2](#ana24630-fig-0002){ref-type="fig"}D, [3](#ana24630-fig-0003){ref-type="fig"}F, and [4](#ana24630-fig-0004){ref-type="fig"}C,G), a custom‐written Python script was used for analysis.

![Human AQP4‐Ig samples induce rapid astrocyte pathology in the murine spinal cord in vivo. (A) Schematic sketch of the setup of the in vivo imaging experiment. Note that NMO and control samples were exchanged three times and replaced by aCSF after 90 minutes. (B) Overview of a typical imaging area in *Aldh1l1*:GFP mice (GFP, green) before application of NMO samples. Boxed area is followed by time lapse in (C), left column. (C) In vivo time‐lapse series of astrocytes (GFP, green) that lose fluorescence and die (red arrows) in the presence of a heat‐inactivated AQP4‐Ig‐containing NMO sample (NMO1) plus HD serum as complement source. Control serum (ctrl2) does not affect astrocytes under the same conditions. Bottom panel shows uptake of the cell death marker, ethidium homodimer (red), which was present during the in vivo recording, in astrocytes that lost fluorescence in response to AQP4‐Ig‐containing serum (boxed area is magnified to the right). (D) Percentage of surviving astrocytes in the presence (0--90 minutes) of control (ctrl) and AQP4‐Ig‐containing NMO samples (NMO) with HD serum as complement source (n = 3--5 recordings per sample; *p* \< 0.001, for NMO1‐3 each tested vs ctrl1, log‐rank test; adjusted to 150 μg/ml for NMO and 300 μg/ml for ctrl samples). (E) Dose response of astrocyte loss as a function of total IgG concentration after 120 minutes for one NMO and several control samples (n = 3--5 recordings per sample, 100--300 μg/ml; n = 1--2 recordings for 0--75 μg/ml). All samples were complemented with the same amount of HD serum (*p* = 0.0045, for NMO1 vs pooled ctrl1‐3 for 300‐μg/ml concentration, Mann--Whitney *U* test). Scale bars, 20 µm in (B), 10 µm in (C). Data are presented as mean ± standard error of the mean. aCSF = artificial cerebrospinal fluid; AQP4 = aquaporin‐4; GFAP = glial fibrillary acidic protein; GFP = green fluorescent protein; HD = healthy donor; Ig = immunoglobulin; NMO = neuromyelitis optica.](ANA-79-794-g002){#ana24630-fig-0002}

![NMO‐related astrocyte pathology is AQP4‐Ig specific and complement dependent. (A) Titration of the NMO patient‐derived sera and control sera in an in vitro binding assay. Antibody titers in serum correspond to the difference in binding to an AQP4‐transduced cell line and a control cell line (delta median fluorescence intensity; ΔMFI). (B) Correlation between the AQP4‐Ig titer and the time when 50% astrocyte loss was reached (t~50~; 150 µg/ml). Mean values are presented as green data symbols. (C) Complement inactivation (complement --) or AQP4‐Ig depletion by an AQP4‐preabsorption column (AQP4 Ig--) abolishes the pathological effects on astrocytes caused by the AQP4‐Ig‐containing NMO1 sample. A preabsorption column without AQP4‐antigen has no effect (AQP4 IgG+; n = 2--5 for all conditions; *p* \< 0.0001, log‐rank test). (D) C1q factor depletion (C1q neg serum+/C1q--) abolishes the pathological effects on astrocytes caused by the NMO1 sample. Resubstitution of purified C1q factor (20 µg/ml) reinstates the effect (C1q neg serum+/C1q+), whereas C1q alone has no effect (C1q neg serum--/C1q+; n = 3 for all conditions; *p* \< 0.0001, log‐rank test). (E) Titration as in (A) of a recombinant AQP4 antibody (r‐AQP4‐IgG) and of a control antibody (r‐ctrl‐IgG). (F) Percent of surviving astrocytes in the presence of r‐AQP4‐IgG and r‐ctrl‐IgG (1.5 µg/ml; n ≥ 3 recordings for all conditions, *p* \< 0.0001, log‐rank test). Data are presented as mean ± standard error of the mean. AQP4 = aquaporin‐4; HD = healthy donor; Ig = immunoglobulin; NMO = neuromyelitis optica.](ANA-79-794-g003){#ana24630-fig-0003}

![AQP4‐antibody mediated astrocyte loss is followed by axonal pathology in vivo. (A) Time‐lapse imaging of the spinal cord in vivo (every 15 minutes for 6 hours) reveals axons that develop progressive swellings in the presence of an AQP4‐Ig‐containing sample (NMO2), whereas in the presence of a control sample (ctrl3), axons remain unaffected. (B) The same experiment as in (A), but without two‐photon imaging. Afterward, the tissue was fixed and images of the spinal cord were taken on a confocal microscope (axons, magenta; astrocytes, green) and quantitatively compared to imaged samples (same data as in C), as shown in the graph on the right (n = 3; *p* = 0.7, Mann--Whitney *U* test). (C) Percentage of swollen axons as a function of time using three different NMO patient‐derived AQP4‐Ig‐containing samples (NMO1‐3; 150 μg/ml) vs three control samples (ctrl1‐3; 300 μg/ml, n \> 120 axons from three experiments for each sample; *p* \< 0.0001, log‐rank test of NMO1‐3 individually vs ctrl1). (D) Example of concomitant quantification of astrocyte survival (green) and axonal swellings (magenta) in one recording using sample NMO2 complemented with HD serum, which were present from 0 to 90 minutes. (E) Correlation between survival of astrocytes and axonal swellings after 6 hours induced by the indicated AQP4‐Ig‐containing samples. Mean values are presented as magenta data symbols. (F) Analogous to Figure [3](#ana24630-fig-0003){ref-type="fig"}C, complement inactivation and AQP4‐Ig depletion abolish the pathological effects of NMO patient‐derived samples on axons (n = 2--3 for each condition; *p* \< 0.0001, log‐rank test; 360 minutes). (G) Percentage of astrocyte survival (green) and axonal swellings (magenta) in the presence of the recombinant AQP4‐antibody (\'r‐AQP4‐IgG\'; 1.5 µg/ml, n \> 125 axons, n = 3; p \< 0.0001 compared to r‐ctrl‐IgG, data not shown, log‐rank test). Scale bars, 10 µm in A and B. Data are presented as mean ± standard error of the mean. AQP4 = aquaporin‐4; HD = healthy donor; Ig = immunoglobulin; NMO = neuromyelitis optica; OFP = orange fluorescent protein.](ANA-79-794-g004){#ana24630-fig-0004}

Statistical Analyses {#ana24630-sec-0015}
--------------------

The proportion of surviving astrocytes and of axons with swellings was analyzed with Kaplan‐Meier estimates, and treatment differences were compared with log‐rank test. For control experiments (axon damage without time lapse), we used nonparametric tests. For comparison of two conditions, we used the Mann--Whitney *U* test; for comparison of more than two conditions, we used Kruskal‐Wallis\' followed by Dunn\'s multiple comparison test. For histopathology, normal distribution of values obtained from individual analyzed fields of view was confirmed using D\'Agostino and Pearson\'s normality test, followed by analysis of variance and Holm‐Sidak\'s multiple comparisons test. Data are shown as mean ± standard error of the mean (SEM); significance statements are included in the figure legends.

Results {#ana24630-sec-0016}
=======

NMO Patient‐Derived AQP4 Antibodies Induce Acute Astrocyte Pathology Ex Vivo {#ana24630-sec-0017}
----------------------------------------------------------------------------

As a first step toward establishing an in vivo assay for NMO‐related neuropathology, we used isolated mouse brain tissue to (1) confirm that human AQP4‐Ig can bind and damage mouse astrocytes, as shown previously in slice cultures,[36](#ana24630-bib-0036){ref-type="ref"} (2) define the time course, concentration ranges, and complement requirements that characterize these effects, and (3) devise a transgene‐based readout of astrocyte death, taking advantage of astrocyte‐specific GFP expression in *Aldh1l1*:GFP mice.[24](#ana24630-bib-0024){ref-type="ref"} First, we confirmed that our AQP4‐Ig‐containing NMO samples specifically labeled GFAP‐positive astrocytes in mouse spinal cord white matter. This staining was absent on tissue of AQP4‐knockout mice (Fig [1](#ana24630-fig-0001){ref-type="fig"}A) and when we used AQP4‐Ig‐negative serum samples (data not shown). Second, we applied diluted, heat‐inactivated, AQP4‐Ig‐positive NMO (or AQP4‐Ig‐negative control) samples together with a complement source (non‐heat‐inactivated HD serum) to acute brain slices from *Aldh1l1*:GFP mice. Within 60 minutes, we observed swelling and fragmentation of astrocyte processes, as well as rounding of cell somata, followed by loss of fluorescence (Fig [1](#ana24630-fig-0001){ref-type="fig"}B--D, Supplementary Video 1). The degree of astrocyte loss was dose dependent and patient specific (survival of astrocytes after 180 minutes as mean percentage ± SEM, average of 3 experiments each: 42.1 ± 5.8 and 63.9 ± 7.3 for two different AQP4‐Ig‐positive NMO samples, one of which \[NMO1\] is illustrated in Fig [1](#ana24630-fig-0001){ref-type="fig"}E,F). In contrast, control sera had no effects over our observation period of 3 hours (100.0 ± 0.0, 99.4 ± 0.6,and 99.6 ± 0.4 for three control sera and three repeats each) --- moreover, in subsequent experiments, we found the toxic effects of these NMO samples to be specifically mediated by AQP4‐Ig and the classical complement cascade (see below). Together, these experiments confirmed the notion that NMO patient‐derived AQP4‐Ig induce astrocyte pathology, which we could follow dynamically using *Aldh1l1*:GFP mice.

Human AQP4 Antibodies Exert Acute Pathological Effects in Mouse Spinal Cord In Vivo {#ana24630-sec-0018}
-----------------------------------------------------------------------------------

To establish an in vivo model of NMO‐related astrocyte toxicity, we first confirmed that a quasi‐intrathecal route of application (application into a laminectomy with dura removal) would suffice to induce astrocyte pathology. We chose this approach because it is compatible with the in vivo imaging technique we sought to employ, which depends on a surgical exposure of the dorsal spinal cord, but also because NMO patients can harbor substantial amounts of AQP4‐Ig in their CSF (as well as plasma blasts that secrete such antibodies).[8](#ana24630-bib-0008){ref-type="ref"}, [9](#ana24630-bib-0009){ref-type="ref"}, [10](#ana24630-bib-0010){ref-type="ref"}, [23](#ana24630-bib-0023){ref-type="ref"} To determine astrocyte pathology in this setting, we performed standard histopathological analysis after a 3‐hour treatment with an AQP4‐Ig‐positive NMO sample plus HD serum applied to a laminectomy. We found a clear reduction in GFAP staining in the superficial spinal cord. At the same time, an oligodendrocyte marker remained unchanged, confirming astrocyte‐specific toxicity of AQP4‐Ig‐containing NMO samples in the presence of complement (Fig [1](#ana24630-fig-0001){ref-type="fig"}G,H) as shown previously for intraparenchymal injections.[16](#ana24630-bib-0016){ref-type="ref"}

Next, we took advantage of a two‐photon imaging approach to visualize cells in the dorsal spinal cord of anesthetized mice.[21](#ana24630-bib-0021){ref-type="ref"}, [32](#ana24630-bib-0032){ref-type="ref"} After establishing a spinal cord imaging window in *Aldh1l1*:GFP mice, we applied heat‐inactivated AQP4‐Ig‐positive NMO samples (n = 3; NMO1 to NMO3) together with untreated HD serum as a source of complement from 0 to 90 minutes (after which antibodies and complement were replaced by aCSF; the same HD serum at a fixed concentration of 20% was used in all in vivo experiments). This allowed us to follow AQP4‐Ig‐mediated astrocyte toxicity over several hours (Fig [2](#ana24630-fig-0002){ref-type="fig"}A). In line with our ex vivo observations, we found that NMO patient‐derived AQP4‐Ig‐containing samples caused swelling and fragmentation of astrocytes in vivo, followed by loss of fluorescence, which correlated with uptake of the cell‐death marker dye, ethidium homodimer (Fig [2](#ana24630-fig-0002){ref-type="fig"}B,C; Supplementary Video 2). Astrocyte damage was dose dependent and correlated with the AQP4‐Ig titer measured in an in vitro binding assay (Figs [2](#ana24630-fig-0002){ref-type="fig"}D,E and [3](#ana24630-fig-0003){ref-type="fig"}A,B; mean survival of astrocytes ± SEM after 120 minutes at 150 μg/ml in %: NMO1 23.0 ± 8.6, n = 5; NMO2 9.7 ± 4.7, n = 4; NMO3 62.9 ± 7.3, n = 5; t~50~ in min: NMO1 65.1 ± 4.5; NMO2 52.3 ± 7.4; NMO3 89.9 ± 5.1). In the presence of control sera with untreated HD serum astrocytes remained unaffected even at high concentration (300 μg/ml of IgG; mean survival of astrocytes ± SEM after 120 minutes in %: ctrl1 99.1 ± 0.9, n = 3; ctrl2 100.0 ± 0.0, n = 3; ctrl3 98.5 ± 0.8, n = 3). Moreover, for the first hour after application, AQP4‐Ig‐induced cell death appeared to be astrocyte specific. When we performed the same experiments with genetically labeled oligodendrocytes (*Plp*:CreER × *ROSA*:STOP‐TdTomato), we observed no overt loss of fluorescence during a 3‐hour imaging period, even though some oligodendrocyte somata assumed a more rounded shape (mean survival of oligodendrocytes ± SEM after NMO1 application at 150 μg/ml after 120 minutes in %: 97.0 ± 3.0, n = 3).

NMO‐Related Astrocyte Toxicity Is AQP4 Specific and Complement Dependent {#ana24630-sec-0019}
------------------------------------------------------------------------

To further elucidate the characteristics of NMO‐related astrocyte toxicity in our model, we selectively depleted AQP4‐Ig from one NMO sample (plasma sample NMO1) using an AQP4‐preabsorption column, which abolished astrocyte damage (Fig [3](#ana24630-fig-0003){ref-type="fig"}C). A preabsorption column without AQP4 antigen had no effect (mean astrocyte death ± SEM in %: 0.7 ± 0.5, n = 5 vs 78.1 ± 2.1, n = 3 after preabsorption with and without AQP4 on column, respectively; 360 minutes, Ig adjusted to 300 μg/ml in both conditions). Complement inactivation (i.e., heat treatment of the HD serum added with the patient samples) also abrogated astrocyte toxicity (Fig [3](#ana24630-fig-0003){ref-type="fig"}C, mean astrocyte death ± SEM in %: 0.0 ± 0.0, n = 2; 360 minutes), confirming that AQP4‐Ig‐mediated astrocyte toxicity is a two‐component system requiring AQP4‐Ig and complement.[16](#ana24630-bib-0016){ref-type="ref"}, [36](#ana24630-bib-0036){ref-type="ref"} To elucidate which complement activation pathway mediates the observed astrocyte damage, we used (1) C1q‐depleted complement, (2) C1q factor alone, and (3) C1q‐reconstituted complement in the presence of AQP4‐Ig‐containing NMO samples. We found that whereas C1q depletion alone protected astrocytes, toxicity was re‐established by C1q‐reconstitution (Fig [3](#ana24630-fig-0003){ref-type="fig"}D; C1q depletion: 1.8 ± 1.0, n = 3; C1q alone: 0.0 ± 0.0, n = 3; C1q reconstitution: 87.5 ± 5.0, n = 3; 180 minutes; all values mean ± SEM). This implies that our model depends on the classical complement pathway.

To rule out the possibility that the observed effect was influenced by other antibodies or non‐specific factors present in patient samples, we took advantage of the recombinant AQP4‐specific antibody 7‐5‐53 (r‐AQP4‐IgG), which was generated from a clonotypic plasma blast present in the CSF of an NMO patient.[9](#ana24630-bib-0009){ref-type="ref"} When combined with a human complement source, a low concentration of r‐AQP4‐IgG (1.5 µg/ml) induced robust astrocyte pathology (Fig [3](#ana24630-fig-0003){ref-type="fig"}E,F; mean survival of astrocytes ± SEM after 120 minutes in %: 44.9 ± 8.5 vs 100.0 ± 0.0 for r‐AQP4‐IgG vs r‐ctrl‐IgG, respectively; n = 3 in both conditions).

NMO‐Related Astrocyte Toxicity Leads to Axonal Pathology {#ana24630-sec-0020}
--------------------------------------------------------

Our in vivo model provides a unique opportunity to investigate whether NMO‐related astrocyte toxicity affects surrounding axons, given that axon damage can be followed by two‐photon imaging in great detail.[21](#ana24630-bib-0021){ref-type="ref"}, [22](#ana24630-bib-0022){ref-type="ref"} We used combinatorial transgenic labeling of astrocytes and axons (*Aldh1l1*:GFP × *Thy1*:OFP double transgenic mice) and followed changes in axons for up to 6 hours after application of NMO samples (Figs [2](#ana24630-fig-0002){ref-type="fig"}A and 4A, Supplementary Video 3). With this labeling, we observed widespread secondary axon damage in the form of progressive swellings, which formed along the length of many axons starting at 100--120 minutes after NMO sample application until the end of our 6‐hour observation period (i.e., well beyond the time during which we applied NMO samples, which was discontinued after 90 minutes). This axon pathology was not the consequence of phototoxicity, given that the same percentage of swollen axons was noted, whether or not a time‐lapse series was acquired (Fig [4](#ana24630-fig-0004){ref-type="fig"}B). Axonal swellings occurred after astrocyte loss was well advanced, and the percentage of swollen axons corresponded to the AQP4‐Ig titer and hence the degree of astrocyte loss (Fig [4](#ana24630-fig-0004){ref-type="fig"}C--E; *cf*. Fig [3](#ana24630-fig-0003){ref-type="fig"}A). After application of control sera, even at high concentrations, no change of axonal morphology could be observed (Fig [4](#ana24630-fig-0004){ref-type="fig"}A,C; mean percentage of axonal swellings ± SEM after 360 minutes: NMO1, 34.3 ± 2.1; NMO2, 66.5 ± 4.1; NMO3, 21.1 ± 7.2 vs with ctrl1, 2.3 ± 2.4; ctrl2, 0.0 ± 0.0, ctrl3, 1.5 ± 1.3; n = 3 for all conditions; 150 μg/ml IgG for NMO, 300 μg/ml for ctrl samples). Notably, we did not observe axon fragmentation, which we previously demonstrated in other models of autoimmunity[21](#ana24630-bib-0021){ref-type="ref"} or after blunt trauma.[22](#ana24630-bib-0022){ref-type="ref"} Indeed, even after prolonged exposure to AQP4‐Ig (NMO1) and HD for 8 hours (mean percentage astrocyte death ± SEM: 98.8 ± 0.6; mean percentage of axonal swellings ± SEM: 65.7 ± 6.7; n = 3), axons remained apparently continuous (Supplementary Video 4). Inactivation of the complement source or AQP4‐Ig depletion from NMO samples abolished the effect on axons, suggesting that axonal pathology depends on AQP4‐mediated astrocyte toxicity (Fig [4](#ana24630-fig-0004){ref-type="fig"}F; complement inactivation: 0.0 ± 0.0, n = 2; AQP4‐immunoglobulin depletion: 0.0 ± 0.0, n = 3 vs. preabsorption column without AQP4‐antigen: 32.8 ± 4.5, n = 3; all values mean ± s.e.m.). Performing the same experiments with recombinant AQP4‐antibodies confirmed that r‐AQP4‐IgG in the presence of complement is sufficient to induce the observed secondary axonal changes with a similar relation to astrocyte damage as observed with AQP4‐Ig‐containing samples (Fig [4](#ana24630-fig-0004){ref-type="fig"}G; axon swellings in %: r‐AQP4‐IgG: 46.7 ± 6.3 vs r‐ctrl‐IgG 0.0 ± 0.0; n = 3 for each condition; all values mean ± SEM).

Discussion {#ana24630-sec-0021}
==========

Here, we use in vivo spinal imaging to reveal the temporal progression of NMO‐related spinal cord pathology induced by AQP4‐Ig and provide new insights into how antibody‐mediated astrocyte damage affects nonastrocytic structures in the spinal cord. Astrocyte toxicity was specific to AQP4‐Ig, correlated with antibody titer, and was mediated by the classical complement pathway. Our study extends previous reports on the potency of human AQP4‐IgG to induce NMO‐related astrocyte pathology in rodents,[9](#ana24630-bib-0009){ref-type="ref"}, [13](#ana24630-bib-0013){ref-type="ref"}, [14](#ana24630-bib-0014){ref-type="ref"}, [16](#ana24630-bib-0016){ref-type="ref"} while at the same time providing a unique dynamic view of astrocyte injury. Moreover, using combinatorial labeling, we found that after AQP4‐Ig‐induced astrocyte loss, axons rapidly developed progressive swellings. Although axonal changes in NMO lesions in the spinal cord have been described in autopsies[11](#ana24630-bib-0011){ref-type="ref"}, [12](#ana24630-bib-0012){ref-type="ref"}, [19](#ana24630-bib-0019){ref-type="ref"} and histopathological evidence of axonal injury was found 12 hours after injection of NMO serum in mouse brain,[16](#ana24630-bib-0016){ref-type="ref"} to our knowledge, this is the first study to directly monitor the development of acute (on the order of hours) axonal pathology in an experimental NMO‐related animal model. Notably, axon damage in this NMO‐related model showed some unique features. Similar to experimental autoimmune encephalomyelitis (EAE), a widely used rodent model of MS, axons exposed to AQP4‐IgG and complement developed early focal swellings. In EAE, however, swollen axons are often severed,[21](#ana24630-bib-0021){ref-type="ref"} an irreversible form of damage commonly observed after blunt trauma.[22](#ana24630-bib-0022){ref-type="ref"} Such axonal transections were not evident in our NMO‐related model, at least during the first 8 hours, suggesting that there could be potential for reversing axonal damage early in an NMO lesion, as has been observed previously in other models of neuronal damage.[21](#ana24630-bib-0021){ref-type="ref"}, [22](#ana24630-bib-0022){ref-type="ref"}, [37](#ana24630-bib-0037){ref-type="ref"}, [38](#ana24630-bib-0038){ref-type="ref"} In addition to revealing new aspects of axon injury, our in vivo model also allows investigating the propagation of injury across the glial‐neuronal network starting from a well‐defined initial lesion to astrocytes. In contrast, in other neuroinflammatory models such as EAE, damage results from a complex and protracted immune insult involving both the innate and adaptive immune systems, where cellular and humoral components operate in parallel to injure multiple CNS targets. In addition, the co‐visualizing myelin and oligodendrocytes with astrocytes and axons in vivo[21](#ana24630-bib-0021){ref-type="ref"}, [31](#ana24630-bib-0031){ref-type="ref"} will allow us to dissect the temporal sequence and inter‐relatedness of the mechanisms governing NMO and other autoantibody‐mediated CNS pathologies.

What is the mechanism driving the rapid axonal changes? Based on our experience,[21](#ana24630-bib-0021){ref-type="ref"}, [22](#ana24630-bib-0022){ref-type="ref"}, [32](#ana24630-bib-0032){ref-type="ref"} use of recombinant reagents, and detailed controls, neither additional components in human samples, imaging, or transgenic labeling can account for the axonal swellings (for details, see Materials and Methods). Although we cannot exclude a possible direct "by‐stander" attack of activated complement factors or an indirect effect by another cell type,[39](#ana24630-bib-0039){ref-type="ref"} the timing, lack of associated pathology, and localization of the axonal changes make these unlikely, and suggest that axonal swelling is the consequence of astrocyte loss. Indeed, this is not entirely surprising,[40](#ana24630-bib-0040){ref-type="ref"}, [41](#ana24630-bib-0041){ref-type="ref"}, [42](#ana24630-bib-0042){ref-type="ref"} given that numerous vital interactions between astrocytes and axons have been documented[43](#ana24630-bib-0043){ref-type="ref"}, [44](#ana24630-bib-0044){ref-type="ref"}, [45](#ana24630-bib-0045){ref-type="ref"}, [46](#ana24630-bib-0046){ref-type="ref"}: For example, astrocytes are known to scavenge glutamate,[47](#ana24630-bib-0047){ref-type="ref"} and excitotoxicity has been implicated in axonal pathology during neuroinflammation.[48](#ana24630-bib-0048){ref-type="ref"}, [49](#ana24630-bib-0049){ref-type="ref"}, [50](#ana24630-bib-0050){ref-type="ref"} This, together with the well‐established role of excitotoxicity after hypoxia,[43](#ana24630-bib-0043){ref-type="ref"}, [51](#ana24630-bib-0051){ref-type="ref"} warrants future investigation in our NMO‐related model using in vivo real‐time optical techniques,[52](#ana24630-bib-0052){ref-type="ref"} calcium sensors,[22](#ana24630-bib-0022){ref-type="ref"}, [53](#ana24630-bib-0053){ref-type="ref"} and selective pharmacological inhibitors. Alternatively, astrocyte loss could also reduce metabolic support for axons,[46](#ana24630-bib-0046){ref-type="ref"}, [54](#ana24630-bib-0054){ref-type="ref"}, [55](#ana24630-bib-0055){ref-type="ref"}, [56](#ana24630-bib-0056){ref-type="ref"} impair oxidative defense,[40](#ana24630-bib-0040){ref-type="ref"}, [57](#ana24630-bib-0057){ref-type="ref"}, [58](#ana24630-bib-0058){ref-type="ref"}, [59](#ana24630-bib-0059){ref-type="ref"} or alter ion and water homeostasis,[60](#ana24630-bib-0060){ref-type="ref"} predisposing axons to swelling.[61](#ana24630-bib-0061){ref-type="ref"} Optical monitoring of these injury mechanisms within our novel NMO model system will provide a powerful means to understand the processes underlying axon damage that emerges secondary to astrocyte loss.

Despite many advantages, our NMO‐related model has a number of limitations. For instance, the poor intrinsic activity of complement and the presence of inhibitors of the classical activation pathway in mice[62](#ana24630-bib-0062){ref-type="ref"} require the use of human complement with NMO samples similar to previous experimental models.[9](#ana24630-bib-0009){ref-type="ref"}, [13](#ana24630-bib-0013){ref-type="ref"}, [15](#ana24630-bib-0015){ref-type="ref"}, [16](#ana24630-bib-0016){ref-type="ref"} Whereas we could control for this additional cause of variability by dissociating the source of AQP4‐Ig and of human complement, natural NMO lesions would use endogenous complement and hence may have different kinetics or a distinct spectrum of injury than observed in our model. Similarly, the direct application of AQP4‐Ig onto a large area of exposed pial surface does not match the widely assumed primary entry route of serum AQP4‐Ig by a disrupted BBB.[5](#ana24630-bib-0005){ref-type="ref"} Nevertheless, the concentration of serum antibodies that we applied to the spinal cord is not outside the range of levels found in NMO patients, especially during relapses.[23](#ana24630-bib-0023){ref-type="ref"} Moreover, plasma blasts and plasma cells can be present in the CSF of NMO patients and locally release AQP4‐Ig,[9](#ana24630-bib-0009){ref-type="ref"}, [63](#ana24630-bib-0063){ref-type="ref"} suggesting that even in this respect our approach is compatible with some of the access routes of AQP4‐Ig in human NMO.

In conclusion, we report here that human NMO‐derived AQP4‐Ig applied to the spinal cord in vivo can reproduce important features of NMO lesion formation, which can be monitored by in vivo imaging. Our results confirm that astrocyte loss appears to be the primary event of AQP4‐Ig‐induced lesion formation and rapidly results in axonal pathology. Our new approach can shed light on the interdependence of astrocyte health and axon survival in white matter tracts and potentially define a window of opportunity for neuroprotective interventions in NMO.
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